



HALYARD HEALTH FACT SHEET



OUR NAME: HALYARD [hal-yerd]: A nautical term referring to the line used for hoisting the sails that propel a ship forward.

PROFILE: Halyard Health is a medical technology company focused on eliminating pain, speeding recovery and preventing infection for healthcare providers and their patients. Halyard Health sells its recognized brands and products in more than 100 countries, and holds leading market positions in multiple categories across its portfolio. Halyard Health is traded on the New York Stock Exchange under the ticker symbol "HYH".

MISSION: To advance health and healthcare by preventing infection, eliminating pain and speeding recovery.

HEADQUARTERS: Alpharetta, Georgia


LOCATIONS: 14 manufacturing facilities worldwide

EMPLOYEES: 12,000 globally


2016 NET SALES: \$1.6 billion

BUSINESS SEGMENTS: Halyard Health is comprised of two business segments: Medical Devices and Surgical & Infection Prevention (S&IP).


2016 NET SALES BY SEGMENT ¹



2016 OP BY SEGMENT ¹



2016 NET SALES BY REGION



The products and solutions of Halyard Health are designed to address some of today's most important healthcare needs, namely, reducing the use of opioids while helping patients recover faster and preventing infection.

Halyard Health is focused on growing its Medical Devices business in a more than \$6 billion addressable market. In 2016, Halyard Health completed its first acquisition with the purchase of CORPAK, a leader in the enteral feeding market with diverse products, which complement the company's digestive health portfolio.

Halyard Health has operated the S&IP business for more than 40 years, maintaining its market leading positions by introducing value-based solutions.

Halyard Health is vertically integrated and manufactures most of its products. Each Medical Devices category and the S&IP business is supported by a dedicated global sales force, a customer support team with significant industry experience and robust product training, and customer education programs.


Medical Devices: This business focuses on pain management, digestive and respiratory health and is comprised of a diverse set of solutions and therapies focused on improving patient outcomes, reducing opioid usage, increasing patient safety and reducing the cost of care including:

- Non-opioid surgical pain technologies
- Minimally-invasive interventional (or chronic) pain therapies
- Closed airway suction systems and feeding tubes



Surgical & Infection Prevention: This business holds several leading market positions, provides products that help prevent healthcare-associated infections (HAIs) and provides protection for both healthcare workers and patients including:

- Surgical drapes and gowns and disposable sterilization wrap
- Exam gloves, facial protection and protective apparel




**BUSINESS
STRATEGY:**

Invest in innovation and growth initiatives to advance transformation into a leading Medical Devices company:

- Continue acquisition strategy
- Increase research and development investment
- Execute cost transformation



SELECTED HISTORICAL FINANCIAL DATA†



† Adjusted data. Visit company website (www.halyardhealth.investorroom.com) for discussion of adjustments and certain reconciliations to GAAP data.

SUMMARY OF BALANCE SHEET AND OTHER DATA†

| (\$'s in millions) | As of December 31, | | |
|------------------------------------|--------------------|-------|-------|
| | 2014 (a) | 2015 | 2016 |
| Balance Sheet Data: | | | |
| Working Capital | \$328 | \$361 | \$269 |
| Primary Working Capital (b) | 348 | 365 | 290 |
| Property, Plant and Equipment, Net | 278 | 280 | 261 |
| Total Assets | 2,518 | 2,000 | 2,072 |

a) The 2014 Consolidated Balance Sheet has been revised to reflect the treatment of \$10 million of deferred financing cost as a reduction of long-term debt.

b) Primary working capital consists of accounts receivable, net of allowances plus inventories, less trade accounts payable

| (\$'s in millions) | For the Year Ended December 31, | | |
|-------------------------------|---------------------------------|------|------|
| | 2014 | 2015 | 2016 |
| Other Data: | | | |
| Capital Spending | \$79 | \$70 | \$29 |
| Depreciation and Amortization | 85 | 65 | 65 |

†The selected historical consolidated and combined financial data should be read in conjunction with our audited historical consolidated and combined financial statements and the related notes contained in our Form 10-K for the year ended December 31, 2016 and filed with the Securities and Exchange Commission. The historical consolidated and combined financial statements and other data represent the global operations of Halyard Health and its subsidiaries as an independent, publicly-traded company beginning on November 1, 2014, and a combined reporting entity derived from Kimberly-Clark's consolidated financial statements and accounting records using the historical results of operations and bases of the assets and liabilities of Kimberly-Clark's businesses and give effect to allocations of expenses from Kimberly-Clark prior to November 1, 2014. The historical consolidated and combined financial statements and other data have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Our 2014 historical consolidated and combined financial statements and other data are not indicative of our future performance and does not reflect what our financial position and results of operations would have been had we operated as a separate, stand-alone public company during the periods shown.

For more complete information, please refer to the Halyard Health website at: <https://halyardhealth.investorroom.com>

Halyard OR Simulation Lab



BUSINESS STRENGTHS:

- A growing and innovative Medical Devices business with solutions that reduce cost and improve quality of care
- An established portfolio of S&IP products with leading market positions and significant brand recognition
- An existing global commercial infrastructure
- A vertically integrated manufacturer
- Strong cash flow
- A strong management team with significant healthcare experience

MANAGEMENT:



Robert E. Abernathy



Rhonda D. Gibby



Christopher G. Isenberg



Christopher M. Lowery



Warren J. Machan



Steven E. Voskuil



John W. Wesley

Robert E. Abernathy, Chairman of the Board and Chief Executive Officer

Rhonda D. Gibby, Senior Vice President and Chief Human Resources Officer

Christopher G. Isenberg, Senior Vice President – Global Supply Chain and Procurement

Christopher M. Lowery, Senior Vice President and Chief Operating Officer

Warren J. Machan, Senior Vice President – Business Strategy

Steven E. Voskuil, Senior Vice President and Chief Financial Officer

John W. Wesley, Senior Vice President, General Counsel



HALYARD

For more information, please visit:

www.halyardhealth.com  

WEBSITE: <https://halyardhealth.investorroom.com>

INVESTOR CONTACT: investor.relations@hyh.com

MEDIA CONTACT: corporate.mediarelations@hyh.com

Call 1-844-HALYARD (1-844-425-9273) in the United States and Canada.

*Registered Trademark or Trademark of Halyard Health, Inc. or its affiliates. © 2017 HYH. All rights reserved. C171909

